|
|
|
|
|
North America's largest commercial stem cells and regenerative medicine conference
Now in its second year, Stem Cells USA & Regenerative Medicine Congress brings together industry leaders from big pharma, biotechs, government and research organizations to address the opportunities and challenges for commercialization of stem cells and regenerative medicine. Translate your novel technology into a commercially viable business.
|
Stem Cells USA & Regenerative Medicine Congress brings together successful biotechs, big pharmas, investors, academics, and governments to discuss opportunities and challenges in the exciting field of stem cells and regenerative medicine.
You will hear from industry leaders about their strategies in managing IP issues, obtaining funds, overcoming manufacturing bottlenecks, and determining partnership models. Discover viable business models unique to stem cells and regenerative medicine, identify good manufacturing practice for your product, and learn how to benefit from your technology through patents and licensing.
» Register now and save $$$
» Download conference brochure
Key themes at this year's conference:
|
2010 speakers include:
 |
Alan Russell
Director
McGowan Institute for Regenerative Medicine
|
 |
Wise Young
Founding Director
W.M. Keck Center for Collaborative Neuroscience
|
 |
Gil Van Bokkelen
Chief Executive Officer
Athersys, Inc.
|
 |
Geoff MacKay
President and CEO
Organogenesis
|
 |
Katie Rielly-Gauvin
Vice President, Regenerative Medicine
Johnson & Johnson Development Corp.
|
 |
Dan Shoemaker
Chief Technology Officer
Fate Therapeutics
|
|
 8 reasons why you can't afford to miss this event:
| 1. Partner with big pharma. Hear from Pfizer, Roche, Bristol-Myers Squibb, AstraZeneca, Johnson & Johnson and Merck as they discuss their current activities, plans for the future, and real life case studies. |
5. Find your optimal business model. Hear from successful biotech companies and learn their strategies to overcoming obstacles. Identify key drivers of value and select the optimal business platform for your project. |
| 2. Meet new investors. Network with venture capital firms and get funding for your projects. |
6. Create value. Learn how to manage your licensing agreements and obtain patents. |
| 3. Overcome processing and manufacturing bottlenecks. Challenges and opportunities associated with autologous and allogenic. Adopt the best approach. |
7. Manage your biotech portfolio. Assess the worth of your biotech investment as a buyer, investor, or seller. Determine your risk tolerance and forecast the probability. |
|
4. Enhance your manufacturing and production structure. Identify the most efficient and cost-effective method of manufacturing for your project.
|
8. Unparalleled opportunities to build and broker relationships. A delegate list that reads like an industry who's who. Ensure you are on the list.
|
|
|
|
|
|
|
|
|
|
|
